[{"orgOrder":0,"company":"Dren Bio","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"DR-01","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dren Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Dren Bio \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dren Bio \/ Taiho Ventures"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dren Bio","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"","sponsorNew":"Dren Bio \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Dren Bio \/ Pfizer Inc"}]

Find Clinical Drug Pipeline Developments & Deals by Dren Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : The strategic collaboration will focus on the discovery and development of therapeutic bispecific antibodies for selected oncology targets using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.

Brand Name : Undisclosed

Molecule Type : Large molecule

Upfront Cash : $25.0 million

January 11, 2022

Lead Product(s) : Bispecific Antibody

Therapeutic Area : Oncology

Highest Development Status : Discovery

Sponsor : Pfizer Inc

Deal Size : $1,025.0 million

Deal Type : Collaboration

blank

02

Pharma, Lab & Chemical Expo
Not Confirmed
Pharma, Lab & Chemical Expo
Not Confirmed

Details : Dren will utilize the proceeds to advance its two lead programs through early clinical development. Dren’s first program, DR-01, is an antibody-based therapy to treat rare leukemias and lymphomas as well as specific phenotypes of auto-immune disorders.

Brand Name : DR-01

Molecule Type : Large molecule

Upfront Cash : Undisclosed

October 16, 2020

Lead Product(s) : DR-01

Therapeutic Area : Oncology

Highest Development Status : Undisclosed

Sponsor : Taiho Ventures

Deal Size : $60.0 million

Deal Type : Series A Financing

blank